Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck 3Q08 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Merck 3Q08

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck

3Q Revenues: $5.9 billion (-2%)

3Q Earnings: $1.1 billion (-28%)

YTD Revenues: $17.8 billion (-1%)

YTD Earnings: $6.2 billion (+26%)

Comments: Januvia sales were $379 million in the quarter (+105%). Sales of Isentress were $107 million. Worldwide sales of Singulair were $1.0 billion (+1%). Cozaar and Hyzaar sales were $888 million (+9%). Combined worldwide sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough joint venture, were $1.1 billion in the quarter (-15%). Worldwide sales of the Gardasil were $401 million (-4%). R&D expenses were $1.2 billion in the quarter (-19%). Restructuring costs, primarily related to employee separation costs associated with the company’s global restructuring programs, were $757 million in the quarter and $49 million in 3Q07.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters